Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes.

Future oncology (London, England) - 1 Oct 2017

Dong Zhi, Gao Jing, Gong Jifang, Li Jie, Li Yanyan, Shen Lin, Li Jian

Abstract excerpt

AIM: To assess the efficacy of second-line sunitinib therapy in gastrointestinal stromal tumor patients with different exon 11 mutation genotypes. PATIENTS & METHODS: Thirty eight of the 75 patients received imatinib (IM) dose escalation followed by sunitinib (IM escalation group), while 37 were switched to sunitinib directly after the failure of first-line IM treatment (sunitinib group). Progression-free...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Substitution

Share to Gastrointestinal Stromal Tumors

Share to Indoles

Share to Pyrroles

Share to Sunitinib

Share to Treatment Failure

Source

Identifiers

PMID: 28685593
DOI: 10.2217/fon-2017-0252

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes.PMID 28685593Read ↗

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.Semantic proximity Read ↗

Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.Semantic proximity Read ↗

Optimal use of targeted agents for advanced gastrointestinal stromal tumours.Semantic proximity Read ↗

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.Semantic proximity Read ↗

Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene.Semantic proximity Read ↗

Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.Semantic proximity Read ↗

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.Semantic proximity Read ↗

Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.Semantic proximity Read ↗

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.Semantic proximity Read ↗

Neoadjuvant Imatinib in Locally Advanced Gastrointestinal stromal Tumours, Will Kit Mutation Analysis Be a Pathfinder?Semantic proximity Read ↗

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.